Viyash Scientific Q4 FY26 Earnings Transcript Released; Strong Growth Reported
Viyash Scientific released its Q4 FY26 earnings transcript, reporting its strongest quarter with EBITDA over ₹200 crore. FY26 EBITDA grew 59.6% and PAT by 1,324%. Total revenue for FY26 reached ₹3,420 crore. The company is focusing on growth in animal and human health formulations, API, and CDMO businesses. Key priorities for FY27 include merger synergies and operational improvements.
The announcement details strong financial performance, strategic business developments, and future growth plans across multiple segments, which are material to investors and the company's valuation.
The company reported its strongest quarter ever, significant year-on-year growth in EBITDA and PAT, and a positive outlook for future growth across its business segments. The credit rating upgrade further supports the positive sentiment.
Viyash Scientific Limited (formerly Sequent Scientific Limited) has released the earnings call transcript for the quarter and year ended March 31, 2026. The company highlighted that Q4 FY26 was its strongest quarter in history, with EBITDA surpassing ₹200 crores. For the full fiscal year 2026, EBITDA saw a significant increase of 59.6% and Profit After Tax (PAT) grew by 1,324% compared to the previous year.
The company described FY26 as a transformative year, marked by successful integration of business operations and corporate functions, leading to improved execution and operating leverage. Viyash Scientific is exploring both organic and inorganic growth opportunities, supported by a deleveraged balance sheet.
In the animal health formulation business, all regions are experiencing strong growth, driven by new product launches and geographical expansion. Manufacturing expansions in Spain and capacity debottlenecking in Turkey are underway. The human health formulation business also performed well, with a strategy shift towards more complex products and internal API manufacturing.
The API and CDMO business saw its animal health API segment grow to a run rate of INR400 crores after being stable for five years. The company is focusing on R&D, speed, efficiency, and portfolio development for this segment. For human APIs, the focus has been on optimizing the product mix by phasing out commodity products and converting intermediates into API business, leading to improved gross margins.
Financially, for Q4 FY26, total revenue was INR920 crores (up 19.1% YoY), with formulations at INR499 crores (up 28%) and API at INR384 crores (up 5%). Gross margin improved to 55.1%, and adjusted EBITDA rose by 64% to INR200 crores, with margins at 21.7%. PAT turned around from a loss of INR32 crores to a profit of INR66 crores.
For the full FY26, total revenue was INR3,420 crores (up 13.8% YoY). Formulations revenue grew 18% to INR1,866 crores, and API revenue increased 8% to INR1,491 crores. Gross margins expanded to 54.3%, and adjusted EBITDA increased 59.6% to INR702 crores with margins at 20.5%. PAT for the full year increased to INR225 crores from INR16 crores in FY25.
The company's credit rating was upgraded, with long-term rating moving to AA- and short-term rating to A1+. Key priorities for FY27 include strengthening merger synergies, improving operational performance, efficient capital allocation, debt reduction, and maximizing cash flow generation.
The transcript also details discussions on the CDMO business, focusing on life cycle management and specialty products, with a projected 40% growth for innovative business in FY27. The company is also expanding its companion animal business, targeting Europe and India, with plans for R&D and manufacturing infrastructure development. The Boehringer Ingelheim partnership for the India portfolio is also mentioned.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.